AZD2461: Novel PARP Inhibitor for Breast Cancer Research and Drug Resistance

Executive Summary: AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 5 nM against PARP-1 in vitro (APExBIO). It induces G2 phase cell cycle arrest and reduces S phase populations in breast cancer cell lines MCF-7 and SKBR-3 (Schwartz 2022). In BRCA1-mutated mouse tumor models, AZD2461 significantly extends relapse-free survival and shows lower affinity for P-glycoprotein (Pgp) compared to olaparib, suggesting improved efficacy against drug-resistant cancers (APExBIO). The compound is insoluble in water but soluble in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasound), and is stable at -20°C for short-term use. These features establish AZD2461 as a benchmark tool for investigating DNA repair modulation and Pgp-mediated resistance in cancer research.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are nuclear enzymes involved in DNA repair, genomic stability, and programmed cell death. PARP-1 is the most abundant isoform and is essential for base excision repair (BER), a primary pathway for repairing single-strand DNA breaks (Schwartz 2022). Inhibition of PARP-1 leads to the accumulation of DNA damage, resulting in cell cycle arrest and cell death, particularly in cells deficient in homologous recombination repair, such as BRCA1/2-mutated tumor cells. Breast cancer cells with such mutations are highly sensitive to PARP inhibitors. AZD2461 was developed to address limitations of earlier PARP inhibitors by reducing P-glycoprotein (Pgp) affinity, thereby improving efficacy in drug-resistant cancer models (APExBIO).

Mechanism of Action of AZD2461

AZD2461 binds to the catalytic domain of PARP-1, inhibiting its enzymatic activity with an IC50 value of 5 nM under in vitro conditions (APExBIO). This inhibition prevents the addition of poly (ADP-ribose) chains to target proteins, a key step in DNA repair signaling. In breast cancer cell models, AZD2461 treatment causes a significant reduction in viable cell numbers in a dose- and time-dependent manner, with typical effective concentrations ranging from 5 to 50 μM and incubation periods of 48–72 hours (Schwartz 2022). Mechanistically, AZD2461 induces G2 phase cell cycle arrest, decreasing the proportion of cells in S phase and increasing those in G2. In vivo, a single dose inhibits PARP enzymatic activity in KB1P tumor-bearing mice for several hours, with poly(ADP-ribose) (PAR) levels returning to baseline after 24 hours (APExBIO).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 enzymatic activity in vitro with an IC50 of 5 nM (APExBIO, product page).
• In MCF-7 and SKBR-3 breast cancer cell lines, AZD2461 reduces viable cell counts in a concentration- and time-dependent manner (Schwartz 2022, DOI).
• AZD2461 treatment leads to increased G2 phase and decreased S phase populations in treated cells (Schwartz 2022, DOI).
• In BRCA1-mutated KB1P mouse tumor models, AZD2461 prolongs median relapse-free survival compared to vehicle controls (APExBIO, product page).
• AZD2461 shows lower affinity for P-glycoprotein (Pgp) than olaparib, reducing the risk of Pgp-mediated drug resistance (APExBIO, product page).
• AZD2461 is well tolerated in long-term animal studies, with no significant toxicity observed at effective doses (APExBIO, product page).

This article extends beyond AZD2461: Novel PARP Inhibitor Powering Breast Cancer Research by providing updated evidence on relapse-free survival and clarifying optimal experimental parameters for in vitro and in vivo models. For a systems biology perspective and advanced evaluation methodologies, see AZD2461: Redefining PARP Inhibition Through Systems Biology, which is complemented here with practical usage benchmarks. For troubleshooting and strategic application, AZD2461: Novel PARP Inhibitor Advancing Breast Cancer Research is further clarified by specifying Pgp-affinity data unique to AZD2461.

Applications, Limits & Misconceptions

AZD2461 is primarily used as a research tool to study DNA repair pathway modulation, cell cycle regulation, and drug resistance mechanisms in cancer biology. Its reduced susceptibility to Pgp-mediated efflux makes it suitable for models with multidrug resistance. Application areas include:

• Assessing synthetic lethality in BRCA1/2-deficient cancer cells.
• Extending relapse-free survival in preclinical animal tumor models.
• Evaluating PARP signaling pathway modulation in systems biology workflows.
• Screening for drug resistance in breast cancer lines.

Common Pitfalls or Misconceptions

• AZD2461 is not recommended for use in water-based buffers due to poor solubility; DMSO or ethanol (with ultrasound) is required for stock solutions (APExBIO).
• PARP-1 inhibition by AZD2461 is reversible; PAR levels return to baseline within 24 hours after a single dose in vivo (APExBIO).
• AZD2461 efficacy is primarily demonstrated in BRCA1/2-mutant and Pgp-overexpressing models; non-mutant or low-Pgp-expressing tumors may have different responses (Schwartz 2022).
• The compound is for research use only; it is not FDA-approved for clinical therapy (APExBIO).
• Long-term storage above -20°C or in aqueous solutions can compromise compound stability and efficacy (APExBIO).

Workflow Integration & Parameters

AZD2461 (SKU: A4164) is supplied as a solid with a molecular weight of 395.43, chemical formula C₂₂H₂₂FN₃O₃, and chemical name 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one (APExBIO). For cell culture studies, stock solutions are prepared in DMSO (≥16.35 mg/mL) or ethanol (≥45.2 mg/mL with ultrasound). Recommended working concentrations are 5–50 μM with exposure times of 48–72 hours. Solutions should be freshly prepared or stored at -20°C for short durations. AZD2461 is compatible with standard in vitro viability, cell cycle, and apoptosis assays. For in vivo studies, dosing regimens should be optimized based on mouse model pharmacokinetics and tumor genotype.

Conclusion & Outlook

AZD2461, available from APExBIO, provides a next-generation solution for dissecting PARP signaling and drug resistance in breast cancer research. Its potent PARP-1 inhibition, low Pgp affinity, and proven efficacy in BRCA1-mutated and drug-resistant models underpin its value for preclinical studies. Researchers should adhere to solubility, storage, and dosing guidelines to ensure reproducible results. Ongoing studies are expected to further elucidate its role in synthetic lethality and translational cancer therapy.